These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26705037)

  • 1. [Screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry: an expert consensus].
    Consensus Group for screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry
    Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):476-9. PubMed ID: 26705037
    [No Abstract]   [Full Text] [Related]  

  • 2. [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
    Zhang XC; Lu S; Zhang L; Wang CL; Cheng Y; Li GD; Mok T; Huang C; Liu XQ; Wang J; Wang MZ; Zhang YP; Zhou JY; Zhou XY; Lin DM; Yang JJ; Li H; Chen HQ; Zhong WZ; Wu YL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):402-6. PubMed ID: 24060077
    [No Abstract]   [Full Text] [Related]  

  • 3. [Application of immunohistochemistry in diagnosis of ALK-positive non-small cell lung cancer].
    Du X; Zhou XY; Lü N; Li XH; Ying JM; Yang F; Li Y; Sun Y; Zhao M; Zhou LX
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):858-60. PubMed ID: 24507115
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnostics of non-small cell lung carcinoma].
    Salmenkivi K; Knuuttila A
    Duodecim; 2014; 130(7):701-4. PubMed ID: 24772787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making.
    von Laffert M; Stenzinger A; Hummel M; Weichert W; Lenze D; Warth A; Penzel R; Herbst H; Kellner U; Jurmeister P; Schirmacher P; Dietel M; Klauschen F
    Lung Cancer; 2015 Dec; 90(3):465-71. PubMed ID: 26547803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions.
    Huang JL; Zeng J; Wang F; Huang QT; Lu JB; Li XM; Chen WQ; Zhu CM; Jin JT; Lin SX
    Per Med; 2017 Mar; 14(2):99-107. PubMed ID: 29754556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis for ALK positive non-small cell lung cancer].
    Feng Q; Yang X; Lin D
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):61-8. PubMed ID: 25676397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in diagnosis and treatment and whole process management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer].
    Liu X; Chen J
    Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):1-4. PubMed ID: 25877310
    [No Abstract]   [Full Text] [Related]  

  • 11. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of fluorescence in-situ hybridization in diagnosis of ALK-positive non-small cell lung cancer].
    Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):854-6. PubMed ID: 24507113
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
    Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
    Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
    Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
    J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Working Group Meeting on ALK diagnostics in lung cancer.
    Cooper W; Fox S; O'Toole S; Morey A; Frances G; Pavlakis N; O'Byrne K; Dettrick A; Leong T; Rathi V; Spagnolo D; Hemmings C; Singh M; Moffat D; Tsao MS; Wilner K; Buller R; Pitman Lowenthal S; Arifeen S; Binko J; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():11-7. PubMed ID: 24673736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)].
    von Laffert M; Schirmacher P; Warth A; Weichert W; Büttner R; Huber RM; Wolf J; Griesinger F; Dietel M; Grohé Ch
    Pneumologie; 2016 Apr; 70(4):277-81. PubMed ID: 26984109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).
    Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.
    Shackelford RE; Ansari JM; Wei EX; Alexander JS; Cotelingam J
    Pharmacogenomics; 2017 Aug; 18(12):1179-1192. PubMed ID: 28745554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.